1. Association of STAT3 with Cx26 and Cx43 in human uterine endometrioid adenocarcinoma
    URSZULA SULKOWSKA et al, 2016, Oncology Letters CrossRef
  2. STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence
    Benjamin L. Bryson et al, 2017, Cell Cycle CrossRef
  3. Cancer Stem Cell Plasticity Drives Therapeutic Resistance
    Mary Doherty et al, 2016, Cancers CrossRef
  4. Effects of BPA on global DNA methylation and global histone 3 lysine modifications in SH-SY5Y cells: An epigenetic mechanism linking the regulation of chromatin modifiying genes
    Mine Senyildiz et al, 2017, Toxicology in Vitro CrossRef
  5. Human Intervention Study to Assess the Effects of Supplementation with Olive Leaf Extract on Peripheral Blood Mononuclear Cell Gene Expression
    Anna Boss et al, 2016, International Journal of Molecular Sciences CrossRef
  6. MicroRNA-411 Inhibits Cervical Cancer Progression by Directly Targeting STAT3
    Dan Shan et al, 2019, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics CrossRef
  7. Oncostatin M: From Intracellular Signaling to Therapeutic Targets in Liver Cancer
    Alessandra Caligiuri et al, 2022, Cancers CrossRef
  8. Integrated MicroRNA–mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer
    Giulia Bottai et al, 2017, International Journal of Molecular Sciences CrossRef
  9. High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer
    John J. Wallbillich et al, 2017, PLOS ONE CrossRef
  10. Prostaglandin E2 triggers cytochrome P450 17α hydroxylase overexpression via signal transducer and activator of transcription�3 phosphorylation and promotes invasion in endometrial cancer
    Jieqi Ke et al, 2018, Oncology Letters CrossRef
  11. The relationship between lncRNA PCGEM1 and STAT3 during the occurrence and development of endometrial carcinoma
    Qianhui Li et al, 2018, Biomedicine & Pharmacotherapy CrossRef
  12. Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer
    Jieqi Ke et al, 2016, Tumor Biology CrossRef
  13. Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression
    Marie Simonneau et al, 2018, Oncotarget CrossRef
  14. Ulipristal acetate simultaneously provokes antiproliferative and proinflammatory responses in endometrial cancer cells
    Ranka Kanda et al, 2022, Heliyon CrossRef
  15. Using Supervised Learning Methods for Gene Selection in RNA-Seq Case-Control Studies
    Stephane Wenric et al, 2018, Frontiers in Genetics CrossRef
  16. Oncostatin M Reduces Pathological Neovascularization in the Retina Through Müller Cell Activation
    Julian Rapp et al, 2024, Investigative Opthalmology & Visual Science CrossRef
  17. Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer
    Jacob M. Smigiel et al, 2017, Molecular Cancer Research CrossRef
  18. EXPOsOMICs: Meet-in-the-Middle and Network Perturbation
    Christiana A. Demetriou et al, 2019, Unraveling the Exposome CrossRef
  19. Expression of Oncostatin M in Early Gastric Cancer and Precancerous Lesions
    Jihua Shi et al, 2019, Gastroenterology Research and Practice CrossRef
  20. Oncostatin M is a novel biomarker for coronary artery disease – A possibility as a screening tool of silent myocardial ischemia for diabetes mellitus
    Shohei Ikeda et al, 2021, IJC Heart & Vasculature CrossRef
  21. Adipocytokines and disease progression in endometrial cancer: a systematic review
    Irene Ray et al, 2022, Cancer and Metastasis Reviews CrossRef
  22. Oncostatin M is overexpressed in NASH‐related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis
    Giovanni Di Maira et al, 2022, The Journal of Pathology CrossRef
  23. Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling
    D J Junk et al, 2017, Oncogene CrossRef
  24. Oncostatin M: A mysterious cytokine in cancers
    Ali Masjedi et al, 2021, International Immunopharmacology CrossRef